医学
糖皮质激素
淋巴系统
免疫学
癌症研究
细胞凋亡
生物
遗传学
作者
Lauren K. Meyer,Michelle L. Hermiston
出处
期刊:Resistance to targeted anti-cancer therapeutics
日期:2019-01-01
卷期号:: 1-26
标识
DOI:10.1007/978-3-030-24424-8_1
摘要
Glucocorticoids (GC) are an integral component of multi-agent therapy regimens for a wide variety of lymphoid malignancies due to their potential effects to induce apoptosis in cells of the lymphoid lineage. Despite their clinical utility, de novo and acquired resistance to GC is a significant clinical problem that contributes to inferior outcomes for many of these diseases. This review summarizes what is currently known about mechanisms of GC resistance in lymphoid malignancies, with a particular focus on novel therapeutic strategies currently in preclinical or clinical development that are rationally-designed to overcome GC resistance and improve clinical outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI